Connect MM- The Multiple Myeloma Disease Registry

Trial Profile

Connect MM- The Multiple Myeloma Disease Registry

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
    • 25 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Dec 2024.
    • 25 Jun 2017 Results assessing impact of post-autologous stem cell transplant maintenance therapy (lenalidomide (LEN)-based maintenance) on survival outcomes in patients with newly diagnosed multiple myeloma (cohort 1,n=432), presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top